Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults

Vaccine

Volumn 26, Issue 38, 2008, Pages 4947-4954

  Nelson, Jennifer C ^a,b   Jackson, Michael ^a,b   Yu, Onchee ^a   Whitney, Cynthia G ^c   Bounds, Lora ^a   Bittner, Rachel ^a,b   Zavitkovsky, Ann ^a   Jackson, Lisa A ^a,b  

^a CENTER FOR HEALTH STUDIES   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Heptavalent pneumococcal conjugate vaccine; Immunity herd; Pneumonia

Indexed keywords

PNEUMOCOCCUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; COMMUNITY ACQUIRED PNEUMONIA; DISEASE SURVEILLANCE; FEMALE; HOSPITAL PATIENT; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRIORITY JOURNAL; THORAX RADIOGRAPHY;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COMMUNITY-ACQUIRED INFECTIONS; DEMOGRAPHY; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PNEUMONIA; POPULATION SURVEILLANCE; PREVALENCE; RETROSPECTIVE STUDIES; TIME FACTORS; UNITED STATES; VACCINES, CONJUGATE;

EID: 50049131793     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.07.016     Document Type: Article

References (33)

1. Black S., Shinefield H., Fireman B., Lewis E., Ray P., Hansen J.R., et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 19 (2000) 187-195
2. Cutts F.T., Zaman S.M., Enwere G., Jaffar S., Levine O.S., Okoko J.B., et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 365 (2005) 1139-1146
3. Klugman K.P., Madhi S.A., Huebner R.E., Kohberger R., Mbelle N., and Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 349 (2003) 1341-1348
4. Mbelle N., Huebner R.E., Wasas A.D., Kimura A., Chang I., and Klugman K.P. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J Infect Dis 180 (1999) 1171-1176
5. Dagan R., Givon-Lavi N., Zamir O., Sikuler-Cohen M., Guy L., Janco J., et al. Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. J Infect Dis 185 (2002) 927-936
6. Centers for Disease Control and Prevention. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease, United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2005;54:893-97.
7. Black S., Shinefield H., Baxter R., Austrian R., Bracken L., Hansen J., et al. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr Infect Dis J 23 (2004) 485-489
8. Lexau C.A., Lynfield R., Danila R., Pilishvili T., Facklam R., Farley M.M., et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 294 (2005) 2043-2051
9. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Lynfield R., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 348 (2003) 1737-1746
10. Hicks L.A., Harrison L.H., Flannery B., Hadler J.L., Schaffner W., Craig A.S., et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination 1998-2004. J Infect Dis 196 9 (2007) 1346-1354 [Epub 2007 Oct 4]
11. Marston B.J., Plouffe J.F., File T.M., Hackman B.A., Salstrom S.J., Lipman H.B., et al. Incidence of community-acquired pneumonia requiring hospitalisation, Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med 157 (1997) 1709-1718
12. Ruiz-Gonzalez A., Falguera M., Nogues A., and Rubio-Caballero M. Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia. Am J Med 106 (1999) 385-390
13. Gutierrez F., Masia M., Rodriguez J.C., Mirete C., Soldan B., Padilla S., et al. Epidemiology of community-acquired pneumonia in adult patients at the dawn of the 21st century: a prospective study on the Mediterranean coast of Spain. Clin Microb Infect 11 (2005) 788-800
14. Black S.B., Shinefield H.R., Ling S., Hansen J., Fireman B., Spring D., et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 21 (2002) 810-815
15. Jackson L.A., Neuzil K.M., Yu O., Benson P., Barlow W.E., Adams A.L., et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 348 (2003) 1747-1755
16. Hansen J., Black S., Shinefield H., Cherian T., Benson J., Fireman B., et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Pediatr Infect Dis J 25 (2006) 779-781
17. Moore M.R., Gertz Jr. R.E., Woodbury R.L., Barkocy-Gallagher G.A., Schaffner W., Lexau C., et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States 2005. J Infect Dis 197 7 (2008) 1016-1027
18. Flannery B., Heffernan R.T., Harrison L.H., Ray S.M., Reingold A.L., Hadler J., et al. Changes in invasive pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization. Ann Intern Med 144 (2006) 1-9
19. Singleton R.J., Hennessy T.W., Bulkow L.R., Hammitt L.L., Zulz T., Hurlburt D.A., et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297 (2007) 1784-1792
20. Huang SS, Platt R, Rifas-Shiman SL, Pelton SI, Goldmann D, Finkelstein JA. Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics 2005;116:e408-13 [Erratum in: Pediatrics 2006;117:593-94].
21. Moore M.R., Hyde T.B., Hennessy T.W., Parks D.J., Reasonover A.L., Harker-Jones M., et al. Impact of a conjugate vaccine on community-wide carriage of nonsusceptible Streptococcus pneumoniae in Alaska. J Infect Dis 190 (2004) 2031-2038
22. Hammitt L.L., Bruden D.L., Butler J.C., Baggett H.C., Hurlburt D.A., Reasonover A., et al. Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. J Infect Dis 193 (2006) 1487-1494
23. Nuorti J.P., Butler J.C., Crutcher J.M., Guevara R., Welch D., Holder P., et al. An outbreak of multidrug-resistant pneumococcal pneumonia and bacteremia among unvaccinated nursing home residents. N Engl J Med 338 (1998) 1861-1868
24. Hausdorff W.P., Feikin D.R., and Klugman K.P. Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis 5 (2005) 83-93
25. van de Garde E.M., Oosterheert J.J., Bonten M., Kaplan R.C., and Leufkens H.G. International classification of disease codes showed modest sensitivity for detecting community-acquired pneumonia. J Clin Epidemiol 60 8 (2007) 834-838
26. Madhi S.A., and Klugman K.P. World Health Organisation definition of "radiologically-confirmed pneumonia" may under-estimate the true public health value of conjugate pneumococcal vaccines. Vaccine 25 13 (2007) 2413-2419 [Epub 2006 Sep 18]
27. Poehling K.A., Talbot T.R., Griffin M.R., Craig A.S., Whitney C.G., Zell E., et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA 295 (2006) 1668-1674
28. Centers for Disease Control and Prevention (CDC). Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction-eight states, 1998-2005. MMWR Morb Mortal Wkly Rep 2008;57(6):144-8.
29. Tsai C.J., Griffin M.R., Pekka Nuorti J., and Grijalva C.G. Changing epidemiology of pneumococcal meningitis after the introduction of pneumococcal conjugate vaccine in the United States. Clin Infect Dis 46 11 (2008) 1664-1672
30. Grijalva C.G., Poehling K.A., Nuorti J.P., Zhu Y., Martin S.W., Edwards K.M., et al. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics 118 (2006) 865-873
31. Grijalva C., Nuorti P.J., Arbogast P.G., Martin S.W., Edwards K.M., and Griffin M.R. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 369 (2007) 1179-1186
32. Poehling K.A., Lafleur B.J., Szilagyi P.G., Edwards K.M., Mitchel E., Barth R., et al. Population-based impact of pneumococcal conjugate vaccine in young children. Pediatrics 114 (2004) 755-761
33. Zhou F., Kyaw M.H., Shefer A., Winston C.A., and Nuorti J.P. Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States. Arch Pediatr Adolesc Med 161 (2007) 1162-1168